Blueprint Medicines (BPMC) Reports Q4 Loss, Misses Revenue Estimates

Core Viewpoint - Blueprint Medicines reported a quarterly loss of $0.79 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.70, but an improvement from a loss of $1.82 per share a year ago [1] Financial Performance - The company posted revenues of $146.37 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.79%, but showing significant growth from $71.96 million in the same quarter last year [2] - Over the last four quarters, Blueprint Medicines has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Blueprint Medicines shares have increased approximately 18.7% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $164.85 million, and for the current fiscal year, it is -$1.43 on revenues of $725.71 million [7] - The estimate revisions trend for Blueprint Medicines is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Blueprint Medicines belongs, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]